HOUSTON--(BUSINESS WIRE)--Regenetech, Inc., the adult stem cell company which has built upon NASA licensed technology, announced that the Company has significantly augmented its cell multiplication capabilities for CD34+38- peripheral blood progenitor cells (adult stem cells). These new results were achieved through the continued development of cell culture conditions for Regenetech’s proprietary and patented Intrifuge™ cellXpansion™ technology. Developing a significant and reliable technology for adult stem cell growth and multiplication currently represents one of the most significant barriers preventing more widespread autologous adult stem cell therapeutic use.
